Gene Translation Laboratory news

12 Dec 2014

Coinciding with the announcement by the WHO about a 50% decrease in number of cases of malaria, TV3 also explains IRB’s discovery of compounds that eliminate malaria in mice. ICREA researcher Lluís Ribas de Pouplana further explains that the treated mice developed an immune memory that protects against future infections.

Watch the TV news (in Catalan)



11 Dec 2014

Cadena Ser radio, like other national and international media, has reported on the results obtained by Lluís Ribas’s team on new borrelidin-based compounds to combat the malaria-causing parasite Plasmodium. This study, published in the PNAS journal, was performed in mice, and showed that the compounds were 100% effective. In addition, the mice developed immune memory against future infections, a feature not achieved previously in an anti-malarial drug.

Listen to the news on Cadena Ser (in Spanish, minute 18)

<p>Analogs of borrelidin to treat malaria (IRB Barcelona)</p>
10 Dec 2014

Researchers at IRB Barcelona identify a family of efficient and selective molecules to combat the parasite Plasmodium, causal agent of malaria.

Two analogues of borrelidin were found to cure 100% of infected mice and produce immunological memory in these animals, a property not previously observed in an antimalarial drug.

Growing resistance to current treatment for malaria increases the need for new drug candidates.

11 Sep 2014

Lluís Ribas is consulted in an article published in Materia about the discovery of a new antibiotic produced by a harmless bacterium present in the human body. This antibiotic acts as a natural defense against other bacteria and opens the door to finding new antibiotics through the analysis of small molecules with bacterial origin in the human body. According to Ribas, an expert on the development of new antibiotics and founder of Omnia Molecular, the potential of this discovery as a way to generate new antibiotics is "incredible."

29 Dec 2013

IRB Barcelona researcher and ICREA professor Lluís Ribas de Pouplana has written an opinion article for the newspaper “El Punt Avui”, in the supplement “Presència”, about the challenges that science in Catalonia faces in 2014.

Ribas feels that an improvement in science requires a substantial shake-up of the university system in order to achieve greater competitiveness as well as to gain full control of the scientific facilities here.

Ribas is optimistic and believes that Catalonia will continue to head science and that centres will keep on attracting young talented researchers. He points out that...

3 Dec 2013

LLuís Ribas, ICREA researcher and co-organizer of the XXIII Barcelona Biomed Conference, explains to Diario Médico the central role of protein synthesis and its relation with many diseases. Ribas explains that there is evidence of errors in gene translation in pathologies such as ELA and Charcot-Marie Tooth, but these are not the only diseases involving such errors.

Related news:

28 November 2013

150 experts in protein synthesis...

28 Nov 2013

From Monday 2 till Wednesday 4 December, the “Institut d’Estudis Catalans” will be hosting the conference “Gene translation: fidelity and quality control”, organized by IRB Barcelona and the BBVA Foundation.

15 Sep 2013

The newspaper ARA publishes a report on the growing resistance to antibiotics of bacterias. The article features the opinion of researcher Lluís Ribas de Pouplana, who through the spin off company, Omnia Molecular, is participating in a European project to discover new drugs.

Read the article in ARA (...

7 Aug 2013

Biocat, the organization that coordinates and promotes the biotechnology, biomedical and medical technology sectors in Catalonia, the BioRegion of Catalonia, reports on the European project Nabarsi, which sees the collaboration of the IRB Barcelona spin off Omnia Molecular. The company, developed by Lluís Ribas de Pouplana, ICREA researcher at IRB, will have a key role in this three-year EU project.

Read the news in Biocat (...

18 Jul 2013

The consortium, called NABARSI, will receive 4.1 million euros of funding from the European Commission and is formed by three public research centres and two companies, among these the IRB Barcelona spin-off Omnia Molecular